Money pours into the nascent industry psychedelic medicinewith dozens of new biotech startups who compete to be among the first to sell mind expanding medications and help against depressionthe addiction and others mental health conditions.
Yes ok psychedelics are still illegal under federal lawcompanies push to try to patent ingredients key found in the hallucinogenic mushroomsayahuasca and other substances that have been used clandestinely for decades or, in some cases, for millennia by indigenous cultures.
The sudden prodigality of Wall Street by hallucinogens has irritated advocates and philanthropists who have long dreamed of making low-cost psychedelics widely available for mental health and personal development. Instead, many now see a very different future for drugs like psilocybin and the LSD: as specialized, expensive drugs controlled by a handful of biotechnology companies.
“It’s disappointing,” said Carey Turnbull, an investor and philanthropist who is part of the board of directors of several non-profit psychedelic organizations. “These for-profit companies are getting all the attention and saying, ‘Wow, this thing is amazing; If I could patent it, I would make a fortune.’”
Since 2010, Turnbull and his wife have donated millions to fund psychedelic research to the New York University, Yale and other top-level academic centers.
The promising results of those studies have caused a wave of popular interest in psychedelics, amplified by books, documentaries and articles that tout its potential to reshape the treatment of mental illness, trauma, and palliative care.
But in recent years, Turnbull has focused on challenging what he and other advocates consider frivolous patents filed by companies entering the field.
Most of the psychedelic startups They are backed by venture capitalists or technology investors looking for the next element capable of “revolutionizing” an industry. Behind one of the largest companies, Atai Life Sciences, is the billionaire from PayPal Peter Thiel, whose enthusiasm for psychedelics is shared by many in Silicon Valley.
Around 50 such companies are now listed on stock exchanges, including companies developing psychedelic drugs, retreats or training programs. Some analysts project the industry could grow to more than $10 billion in the next decade.
:format(jpeg)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/K6S3KIGRANAKHGFJI3MXEICUKU.jpg)
But recently, Investors have retreated amid reminders about the enormous challenges of turning illegal drugs into profitable medicines.
Atai laid off 30% of its staff last March after its depression treatment failed in a key study. Shares are down 80% to 90% from their industry-wide peak prices, and several smaller companies are restructuring or filing for bankruptcy.
“They’re in this cycle of hyperbole, but then you get hit with the reality of having to run a biotech company,” said Chris Yetter of Dumont Global, which manages a large portfolio of cannabis and psychedelic companies. “You run drug trials and some of them are successful and some of them fail, and every quarter your cash runs out.”
The liquidity crisis recently forced fundamental changes to the Multidisciplinary Association for Psychedelic Studies (MAPS), the sector’s leading non-profit organization.
For more than 30 years, MAPS efforts have been funded almost entirely by donations from wealthy individuals, including billionaires like Steven Cohenbaseball team owner New York Metsand Rebekah Mercer, Republican political donor. As a matter of principle, MAPS has never patented its work.
The group’s pharmaceutical arm, MAPS Public Benefit Corp., is expected to receive this year the approval in the United States of the first psychedelic medication accepted for review by the Food and Drug Administration (FDA): MDMA, or ecstasy, to help treat post-traumatic stress disorder.
But as investment opportunities have multiplied, charitable giving has dried up. Recently, the group was forced to accept private investors to continue financing the pharmaceutical company, which changed its name to Lykos Therapeutics.
“We are victims of our own success,” said Rick Doblin, founder of MAPS. “It’s heartbreaking because I was hoping to go all the way with philanthropy, but I couldn’t raise the many millions needed to do it.”
Psychedelics never fit the business model of a traditional blockbuster drug: a proprietary, patent-protected drug that patients take regularly for years.
None of the psychedelics currently being studied are new. Synthetic drugs like LSD and ecstasy have existed off-patent for decades. Natural substances like psilocybin, found in certain mushrooms, cannot be patented on their own.
And then there is the challenge of administering drugs that cause intense, disorienting visions and experiences. All medications competing for FDA approval must be administered under professional supervision, typically over several therapy sessions lasting six to eight hours each.
All those hours and professional fees will increase costs, which many analysts say could range between $5,000 and $10,000 for a course of treatment.
Psychedelic executives say the only way to defer those costs is to conduct the large, rigorous clinical studies required for a FDA approval, which could force insurers to pay for psychedelics. But funding those studies requires raising tens of millions of dollars from investors, who typically only back drugmakers with rigorous patents.
“The only way to achieve that broad and equitable access is with strong intellectual property,” said Kabir Nath, CEO of Compass Pathways, which studies lab-produced psilocybin to treat depression, anorexia and other disorders.
compass is one of the most aggressive companies when it comes to trying to patent its technology, with dozens of applications submitted to the United States Patent and Trademark Office.
One presentation describes the “soft furniture” and “muted colors” that would decorate rooms where patients take psilocybin. Another patent claims a specific microscopic structure in Compass’ synthetic psilocybin, which the company claims is especially suitable for mass production.
The company’s efforts have been mocked by some researchers, who point out that already in the 1970spsychedelic therapists had codified the environments and techniques described in the Compass patents.
“It just seems like a blatant power grab,” said neuroscientist Frederick Barrett, who directs the psychedelic center at Johns Hopkins University.
But attempts to challenge Compass’ synthetic psilocybin patents have been unsuccessful, despite years of work by Freedom to Operate, Turnbull’s nonprofit patent watchdog corporation.
Other companies take more creative approaches to patenting psychedelics, such as reformulating them as dissolvable pills or films, or combining LSD and ecstasy in one pill.. Skeptics point out that this approach of combining LSD and ecstasy, called “candyflipping,” has been used recreationally for decades.
One of the most fascinating reformulation efforts involves trying to shorten the duration of the psychedelic experience, or even eliminate it entirely, without losing psychological benefits for patients.
The rush to innovate worries some psychiatrists who point to the many fundamental questions about psychedelics that remain unanswered, including how exactly they affect the brain and how long their benefits might last.
As companies develop more derivatives and combinations of psychedelics, deciphering their strengths and weaknesses will become more difficult, says Dr. Jeffrey Lieberman of Columbia University. If researchers can’t clearly demonstrate their benefits, they risk another backlash like the 1970 federal ban that killed psychedelic research for decades.
“Psychedelics could have enormous benefits for the treatment of a number of diseases,” Lieberman added. “But if we do it wrong and rush the process, these drugs will be banned again and that opportunity is lost.”
